
DBVT Stock Forecast & Price Target
DBVT Analyst Ratings
Bulls say
DBV Technologies is well-positioned to spearhead the immunotherapy space for pediatric peanut allergy with its novel Viaskin technology platform. Key potential catalysts driving stock performance include the upcoming BLA submissions for children (1H26) and toddlers (2H26), as well as the completion of the COMFORT-TODDLER 6-month supplemental safety study. The company's proforma cash position of ~$284MM is expected to provide sufficient runway into 2Q27 to support operations until commercialization. However, there are some risks to consider, including clinical and regulatory risk, financial risk as the company continues to incur losses, and commercial risks associated with market potential and patient perception of treatment effectiveness. Our analysis, based on a sum-of-the-parts (SOTP) net-present-value (NPV) valuation, sets our PT at $51, considering the probability-adjusted NPV of VIASKIN peanut patch in pediatric peanut allergies, pipeline value, and the company's anticipated YE26 cash position.
Bears say
DBV Technologies is facing delays and setbacks in its Viaskin Peanut treatment for peanut allergies, including issues found in the COMFORT-TODDLER study and the need for additional safety studies requested by the FDA for different age groups. These delays and potential competition in the immunotherapy space could impact the company's future revenue potential. Additionally, the company has reported a significant net loss in the first quarter of 2026 and has a limited cash position, which could potentially lead to a need for additional funding in the future.
This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
DBVT Analyst Forecast & Price Prediction
Start investing in DBVT
Order type
Buy in
Order amount
Est. shares
0 shares